Durable Response to Crizotinib in a MET-Amplified, KRAS-Mutated Carcinoma of Unknown Primary

BACKGROUND: Carcinoma of unknown primary (CUP) accounts for 3–5% of all adult solid tumors. An extensive search for the anatomic site of origin is often undertaken in an attempt to tailor systemic treatment, but the latter often has limited efficacy – especially in the setting of an initial treatmen...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Palma, Norma A., Ali, Siraj M., O'Connor, Jamie, Dutta, Deepa, Wang, Kai, Soman, Salil, Palmer, Gary A., Morosini, Deborah, Ross, Jeffrey S., Lipson, Doron, Stephens, Phil J., Patel, Mayur, Miller, Vincent A., Koutrelakos, Nicholas
Natura: Artigo
Lingua:Inglês
Pubblicazione: S. Karger AG 2014
Soggetti:
Published online: July, 2014
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4164090/
https://ncbi.nlm.nih.gov/pubmed/25232318
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000365326
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi